Teriparatide

Chemical formula: C₁₈₁H₂₉₁N₅₅O₅₁S₂ Molecular mass: 4,116.134 g/mol

Therapeutic indications

Teriparatide is indicated for:

Osteoporosis

Population group: only adults (18 years old or older)

Teriparatide is indicated for treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

20 micrograms once daily

Contraindications

Teriparatide is contraindicated in the following cases:

Pregnancy

Lactation

Hypercalcaemia

Hypercalcemia

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Elevations of alkaline phosphatase

Alkaline phosphatase raised

Skeletal malignancies, bone metastases

Malignant neoplasm of bone

External beam or implant radiation therapy to the skeleton

† Radiotherapy by body site

Metabolic bone diseases

Metabolic bone disease and additionally not Primary osteoporosis and additionally not Osteoporosis caused by corticosteroid

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.